Royalty Pharma plc shareholders approved Authorization to allot shares without pre-emptive rights at the 2026-06-04 meeting.
“Proposal 10. To authorize the Board of Directors to allot shares without rights of pre-emption:”
Royalty Pharma plc — fact timeline
Source-grounded facts extracted from Royalty Pharma plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Royalty Pharma plc shareholders approved Authorization to allot shares at the 2026-06-04 meeting.
“Proposal 9. To authorize the Board of Directors to allot shares:”
Royalty Pharma plc shareholders approved Approval of share purchase agreements and counterparties at the 2026-06-04 meeting.
“Proposal 8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares:”
Royalty Pharma plc shareholders approved Authorization for Board to determine U.K. statutory auditor remuneration at the 2026-06-04 meeting.
“Proposal 7. To authorize the Board of Directors to determine the remuneration of the Company’s U.K. statutory auditor:”
Royalty Pharma plc shareholders approved Re-appointment of Ernst & Young as U.K. statutory auditor at the 2026-06-04 meeting.
“Proposal 6. To re-appoint Ernst & Young as the Company’s U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders:”
Royalty Pharma plc shareholders approved Advisory vote on U.K. directors' remuneration report at the 2026-06-04 meeting.
“Proposal 5. To approve, on a non-binding advisory basis, the Company’s U.K. directors’ remuneration report in the U.K. Annual Report and Accounts:”
Royalty Pharma plc shareholders approved Approval of U.K. statutory accounts and reports at the 2026-06-04 meeting.
“Proposal 4. To approve receipt of the Company’s U.K. statutory accounts together with the Company’s U.K. statutory reports, including the directors’ report, the strategic report, the directors’ remuneration report and the auditors’ report for the fiscal year ended December 31, 2025 ("U.K. Annual Report and Accounts") :”
Royalty Pharma plc shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2026-06-04 meeting.
“Proposal 3. To ratify the appointment of Ernst & Young LLP, as the Company’s independent registered public accounting firm:”
Royalty Pharma plc shareholders approved Advisory vote on executive compensation at the 2026-06-04 meeting.
“Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers:”
Royalty Pharma plc shareholders approved Election of nine directors at the 2026-06-04 meeting.
“Proposal 1. To elect nine directors, each by separate ordinary resolutions, to the Company’s Board of Directors to serve until the 2027 Annual General Meeting of Shareholders:”
Royalty Pharma plc incurred revolving credit of $1.8 billion with Bank of America, N.A., as Administrative Agent at base rate determined by reference to the highest of (1) the administrative agent maturing May 22, 2031.
“Credit Agreement were terminated in full. The Credit Agreement provides for an unsecured revolving credit facility (the “Revolving Credit Facility”) in an amount equal to $1.8 billion that is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal”
Royalty Pharma plc reported first quarter of 2026 results: revenue $925 million. Guidance raised.
“Press Release May 6, 2026 R oyalty Pharma reports first quarter 2026 results Portfolio Rece ipts growth o f 10% to $925 million ; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million”
Vlad Coric was appointed as Director at Royalty Pharma plc.
“Effective April 7, 2025, Dr. Vlad Coric was appointed to serve as a new member of the Board of Directors (the “Board”) of Royalty Pharma plc (the “Company”).”
Royalty Pharma plc updated its first quarter of 2024 guidance (reaffirmed).
“On May 9, 2024, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.